Medical Imaging Software Development: 10 Key Questions for Choosing the Right Technology Partner

FDA data shows that as of September 2026, more than 1,600 AI-enabled medical devices have received authorization. This means "we do medical AI" has shifted from a differentiator to a baseline expectation — in medical imaging software development, what truly separates vendors is their demonstrable capability in interoperability, validation, cybersecurity, and regulatory execution.

Selecting a partner based solely on a portfolio is one of the most common mistakes buyers make. A qualified medical imaging product must reliably handle large-volume study data, preserve clinical context, integrate with existing systems, protect protected health information (PHI), and — where applicable — produce an evidence chain that can withstand regulatory scrutiny. The following ten questions will help you quickly determine whether a vendor genuinely possesses these capabilities.

From DICOM to Regulation: Hard Validation of Technical Capability

Can they demonstrate DICOM and PACS experience in a production environment?

Don't settle for a vendor's verbal claim of "DICOM expertise." The engineering team should be able to clearly explain how they handle DICOM and DICOMweb, QIDO-RS/WADO-RS/STOW-RS, PACS/VNA integration, modality worklists, DICOM metadata, transfer syntaxes, multi-frame studies, de-identification, and viewer interoperability.

DICOMweb, as the REST-based standard for managing and distributing medical images, annotations, reports, and other DICOM objects, is only truly understood by teams who have solved real interoperability problems — not just listed DICOM as a capability tag. Ask how they test PACS integration, handle malformed studies, validate metadata, manage transfer failures, and prove cross-environment compatibility before approving an architecture.

DICOM (Digital Imaging and Communications in Medicine) is the core communication protocol in medical imaging, defining the storage, transmission, and communication format for medical images and related information. Nearly all modern medical imaging devices — CT, MRI, ultrasound, digital X-ray — output data in DICOM format. PACS (Picture Archiving and Communication System) is the foundational infrastructure hospitals use to store, retrieve, distribute, and display medical images. Deep integration of both is a prerequisite for medical imaging software to function in a real clinical environment.

DICOMweb is a RESTful API standard built on top of the traditional DICOM protocol, comprising three core services: QIDO-RS (query imaging objects), WADO-RS (retrieve imaging objects), and STOW-RS (store imaging objects). Compared to traditional DICOM network services, DICOMweb integrates more easily with modern web applications and cloud architectures — but also introduces new interoperability challenges. Different PACS vendors implement DICOMweb differently, and issues like transfer syntax negotiation, streaming large multi-frame studies, and metadata integrity validation are only deeply understood by teams who have handled these edge cases in real production environments.

How do you determine whether your software qualifies as a medical device?

This question must be answered before a single line of code is written. The FDA's regulatory posture depends heavily on intended use and software function. Software that acquires, processes, or analyzes medical images may fall within the medical device regulatory scope rather than qualifying for the exemptions afforded to certain non-device clinical decision support software.

For medical device software development, be clear about who owns: intended use definition, software classification, risk analysis, design controls, verification evidence, and regulatory documentation. If a vendor can only say "we're HIPAA compliant" without being able to discuss device classification, they haven't actually answered the core regulatory question.

How does your development process support FDA and QMSR requirements?

FDA's Quality Management System Regulation (QMSR) took effect on February 2, 2026, incorporating ISO 13485:2016 into the device quality framework. This means traceability must be an intrinsic part of the delivery process — not a documentation sprint crammed in before submission.

Ask for real examples of requirements traceability, risk controls, verification records, change management, defect traceability, and release evidence. Regulatory readiness cannot be retrofitted after engineering is complete. For regulated imaging products, requirements, risks, architecture decisions, tests, defects, releases, and changes must form a traceable evidence chain throughout the entire development lifecycle. A partner who cannot explain this chain will likely generate expensive rework, even if the application appears to function correctly.

QMSR (Quality Management System Regulation, 21 CFR Part 820 revised) is FDA's quality management framework for medical device manufacturers. The most significant change in the version that took effect in February 2026 is the direct incorporation of ISO 13485:2016 requirements into U.S. federal regulations, aligning American standards with international medical device quality norms. ISO 13485 is a quality management system standard specifically designed for the medical device industry; compared to the general-purpose ISO 9001, it imposes stricter requirements around risk management, design controls, and regulatory compliance.

For software development, QMSR compliance is fundamentally expressed through the execution of IEC 62304 (Medical Device Software — Software Life Cycle Processes), which defines specific requirements for software development, maintenance, risk management, and configuration management. The traceability matrix — linking user requirements, software requirements, architectural design, test cases, and risk control measures — is a critical document. FDA reviewers specifically examine whether this evidence chain is complete and continuously maintained throughout development, not assembled at the last minute before submission.

Performance, Interoperability, and Security: The Test of Production-Grade Standards

How do you test imaging performance at clinical scale?

A demo built on ten studies proves almost nothing. Require vendors to define measurable targets across the following dimensions:

Area	Questions to Ask
Viewer	How long until the first diagnostically usable image appears?
Archiving	How many studies can be ingested concurrently?
Network	What happens on slow hospital connections?
Large studies	How are CT/MRI series streamed or prefetched?
Recovery	What happens when a transfer fails mid-way?

These questions separate genuine engineering discipline from generic claims about healthcare software development capability.

What is your interoperability strategy beyond DICOM?

Medical images rarely operate in isolation. Your platform will likely need to integrate with RIS, EHR/EMR, identity management, scheduling, reporting, billing, or clinical workflows via HL7 or FHIR. Mature healthcare custom software development should be designed around data flows:

Modality → PACS/VNA → Viewer → Clinical Workflow → EHR → Reporting

A partner with mature product engineering capabilities should design these system boundaries before accelerating feature development.

How is security engineered into the product?

Don't accept the vague answer "we use encryption." Probe specifically for: role-based access control (RBAC) and least privilege, multi-factor authentication (MFA), encryption in transit and at rest, audit logging, key management, vulnerability management, software bill of materials (SBOM), security updates, incident response, and secure PHI logging.

FDA published updated medical device cybersecurity guidance in February 2026, covering cybersecurity design and premarket documentation requirements. Security in medical imaging software is a lifecycle requirement, not a checkbox at the infrastructure layer. Buyers should evaluate identity controls, PHI handling, auditability, software dependencies, vulnerability response, secure deployment, update mechanisms, and post-release monitoring — encryption alone does not demonstrate a vendor's capability to build or maintain a secure medical product.

SBOM (Software Bill of Materials) has become an increasingly important cybersecurity regulatory requirement for medical devices. It lists all open-source and third-party components and their version information in a machine-readable format. FDA's 2023 cybersecurity guidance explicitly requires medical device manufacturers to submit an SBOM as part of premarket submissions, enabling rapid assessment of device exposure when new vulnerabilities (such as supply chain vulnerabilities on the scale of Log4Shell) are disclosed. For medical imaging software, maintaining an SBOM means the development team must continuously track the vulnerability status of all dependency components — not just perform a static scan at release time.

The secure logging requirements for PHI differ fundamentally from general security logging: the logs themselves cannot contain PHI content (otherwise the logging system itself becomes PHI storage requiring protection), yet must be detailed enough to support forensic analysis of security incidents. This tension imposes specialized requirements on log architecture design — a defining detail that distinguishes medical software security engineering from general enterprise software.

AI, Intellectual Property, and Long-Term Evolution

What is your validation strategy for imaging AI?

The introduction of AI fundamentally changes the evaluation logic. Ask the team how they distinguish between: train/validation/test data separation, model versioning versus application versioning, inference failures versus workflow failures, model performance versus clinical utility, and automated output versus human review.

FDA's expanding landscape of AI-enabled devices makes full lifecycle controls increasingly critical. For AI-assisted products, choose teams who can discuss model evaluation, observability, rollback mechanisms, and human oversight — not just model accuracy.

FDA's regulatory framework for AI/ML-enabled medical devices continues to evolve. The 2021 Action Plan for AI/ML-Based Software as a Medical Device and the subsequent Predetermined Change Control Plan (PCCP) mechanism allow manufacturers to pre-specify the boundary conditions for model updates at the time of approval, enabling iterative model improvements without resubmission. The prerequisite for this mechanism is that manufacturers must establish rigorous model performance monitoring systems capable of continuously tracking performance drift on real clinical data after deployment.

Strict separation of training, validation, and test sets is a baseline requirement for AI medical device evaluation, but clinical scenarios introduce additional complexity: demographic representativeness of training data, generalizability across institutions and devices, annotation quality and inter-annotator consistency, and delineation of responsibility between model output and clinical decision-making. Model accuracy is only the starting point. What regulators care more about is the impact of false negative rates on patient safety, the predictability of model failure modes, and how human review mechanisms intervene when system confidence is insufficient.

Who owns the architecture, data, models, and intellectual property?

This is precisely where many outsourcing contracts become expensive. Before finalizing a partner, clarify ownership of: source code, infrastructure definitions, data schemas, trained models, prompts and evaluation assets, documentation, integration adapters, and deployment pipelines.

Red flag: If switching engineering teams means rebuilding proprietary integration layers, you've purchased a dependency — not custom medical software that genuinely belongs to you.

How will you handle our existing imaging platform?

Many organizations don't need to start from scratch. A capable healthcare software development company should assess whether each component should be retained, encapsulated, refactored, migrated, or replaced. For legacy PACS connectivity platforms, application modernization is often more pragmatic than replacing all workflows at once. Require a migration plan covering parallel operation, DICOM reconciliation, rollback, data validation, and downtime windows.

What evidence can you provide before we sign?

Instead of asking "have you built medical software before?", directly request verifiable artifacts. Use the scorecard below to evaluate with evidence rather than sales demonstrations:

Evidence Item	Weight
DICOM/PACS architecture documentation	20%
Regulatory and validation methodology	20%
Security engineering evidence	15%
Interoperability approach	15%
Performance testing strategy	10%
Migration/rollback plan	10%
IP and handoff terms	10%

Among the many medical software development companies available, real differentiation lies not in the length of a capability list, but in whether engineering decisions can be clearly examined before development risk converts into contractual risk.

The Ultimate Test: Would You Trust This Partner in an Audit or Production Incident?

This is the true selection criterion. A qualified medical device software development services provider should be able to clearly explain what happens when: a PACS rejects study data, an AI model changes, a vulnerability is discovered, validation fails, or a regulator requests evidence.

The winners in medical imaging software development are not the vendors with the longest capability lists — they are the teams who can prove how the system will behave, fail safely, recover, integrate, and remain auditable. Turn these ten questions into hard evaluation criteria, and you'll understand the architecture clearly before committing your engineering budget.